Amgen (NASDAQ: AMGN), a company that says it is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics, yesterday reported its financial results for the first quarter of 2019.

The company reported total revenues of USD5.6bn in the first quarter of 2019.

The firm generated USD1.7bn of free cash flow in the first quarter of 2019 compared with USD2.6bn in the same period in 2018.

Non-GAAP EPS increased 3% to USD3.56 benefited by lower weighted-average shares outstanding.

Product sales declined 1% globally. New and recently launched products including Prolia (denosumab), Repatha (evolocumab) and KYPROLIS (carfilzomib) showed double-digit growth.

Robert A Bradway, chairman and chief executive officer, said, 'We continue to generate strong, volume-driven growth for our newer products, while effectively defending our mature products. We are also advancing a record number of first-in-class molecules targeting significant areas of unmet need through our pipeline.'